OpenAI-backed Chai Discovery raises $130M at $1.3B valuation as AI transforms drug development

OpenAI-Backed Biotech Startup Achieves Unicorn Status

Chai Discovery announced a $130 million Series B funding round on December 15, reaching a $1.3 billion valuation and officially joining the unicorn ranks 1

1

. The round was co-led by General Catalyst and Oak HC/FT, with participation from OpenAI, Thrive Capital, Menlo Ventures, Dimension, Neo, Yosemite venture fund, Lachy Groom, SV Angel, and new investors Glade Brook and Emerson Collective 1

1

. The investment more than doubles the company's previous valuation and brings its total funding to over $225 million . This OpenAI-backed biotech startup represents one of the most prominent examples of Silicon Valley's increasing focus on the intersection of AI and healthcare.

Rapid Progress in AI Drug Discovery

Founded in 2024, Chai Discovery builds foundation models specifically tuned for predicting molecular interactions to accelerate drug development 1

1

. The company's ambition centers on creating a computer-aided design suite for molecules, fundamentally transforming how scientists approach drug design 1

1

. CEO Josh Meier, who previously worked at OpenAI and Facebook, emphasized the accelerating pace of innovation: "We're in awe of the rate of progress on the models -- what looked like five-year problems just months ago are now getting solved in weeks" 4

4

. This dramatic compression of development timelines signals a fundamental shift in the biopharmaceutical sector's approach to drug discovery.

Chai 2 AI Model Delivers Breakthrough Performance

The AI medical research startup released its latest Chai 2 AI model, which achieves significant improvements in success rates for designing custom antibodies from scratch, a process known as de novo antibody design . Unlike competitors' models that often design only protein fragments, Chai 2 can generate full-length mAbs antibodies, along with nanobodies derived from llamas and alpacas, and miniproteins 2

2

. The model provides a "100-fold improvement over previous computational methods" in certain areas 2

2

. In testing, 89% of Chai 2's suggested antibody designs contained either a single issue or none when evaluated across four critical criteria determining whether a molecule could become medicine 2

2

.

Technical Precision Drives Drug Design Success

Chai 2 evaluates antibodies with exceptional granularity, reasoning about structures at sub-angstrom scale—one ten-billionth of a meter, slightly more than the length of a hydrogen atom 2

2

. This precision allows the model to account for multiple factors beyond binding affinity, including manufacturability, safety, and stability—considerations that determine whether a molecule can successfully become a drug 2

2

. Meier stated that "our latest models can design molecules that have properties we'd want from actual drugs, and tackle challenging targets that have been out of reach" 1

1

.

Silicon Valley Bets Big on AI-Powered Healthcare

Chai Discovery joins a surge of AI drug discovery companies attracting substantial investment from tech leaders. Yosemite, the oncology-focused venture firm founded by Steve Jobs' son Reed Jobs, participated in the round, along with Emerson Collective, led by Laurene Powell Jobs . OpenAI CEO Sam Altman has invested in Formation Bio, while LinkedIn co-founder Reid Hoffman launched his own drug discovery startup, Manas, earlier this year . Venture funding for seed- through growth-stage AI-powered health tech companies reached $10.7 billion this year, representing more than 24% increase compared to the $8.6 billion raised in all of 2024, according to Crunchbase data . The company plans to deploy the new capital to expand commercialization efforts while accelerating research and product development . Meier expressed confidence that "we're standing on the precipice of a new era for the biopharmaceutical industry," predicting that AI models "will unleash a new wave of first-in-class and best-in-class therapeutics, and the early adopters in pharma will be the big winners" .